0001415889-24-009334.txt : 20240328
0001415889-24-009334.hdr.sgml : 20240328
20240328163105
ACCESSION NUMBER: 0001415889-24-009334
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240326
FILED AS OF DATE: 20240328
DATE AS OF CHANGE: 20240328
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Johnston John Joseph
CENTRAL INDEX KEY: 0001874850
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40674
FILM NUMBER: 24799619
MAIL ADDRESS:
STREET 1: C/O MAXCYTE, INC.
STREET 2: 22 FIRSTFIELD ROAD, SUITE 110
CITY: GAITHERSBURG
STATE: MD
ZIP: 20878
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MAXCYTE, INC.
CENTRAL INDEX KEY: 0001287098
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 522210438
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-517-5556
MAIL ADDRESS:
STREET 1: 9713 KEY WEST AVENUE,
STREET 2: SUITE 400
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: MAXCYTE INC
DATE OF NAME CHANGE: 20040415
4
1
form4-03282024_040349.xml
X0508
4
2024-03-26
0001287098
MAXCYTE, INC.
MXCT
0001874850
Johnston John Joseph
C/O MAXCYTE, INC.
9713 KEY WEST AVENUE, SUITE 400
ROCKVILLE
MD
20850
true
false
false
false
1
Common Stock
2024-03-26
4
M
0
5000
2.142
A
125583
D
Common Stock
2024-03-26
4
S
0
5000
4.405
D
120583
D
Stock Option (right to buy)
2.142
2024-03-26
4
M
0
5000
0
D
2029-03-04
Common Stock
5000
617
D
The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 28, 2023.
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.37 to $4.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares underlying this option vested monthly in forty-eight (48) equal monthly installments commencing on April 4, 2019.
/s/ Katie Kazem, Attorney-in-Fact
2024-03-28